PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
Sep 15, 2020
Sep 15, 2020

bybhenderson

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that after the conclusion of 4-years of extensive testing, evidence of fully functional retinal cells was conclusively achieved. Based on these results Dr. Kevin Gregory-Evans shortly submitting a paper for publication in a peer reviewed journal.   In vivo tests demonstrated that...Read more
Marietta, Ohio, November 23, 2021 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has selected two formulations of its Anti-Aging Glycopeptide (AAGP®) product to be advanced into preclinical efficacy testing for the topical treatment of dry eye disease and ocular inflammation. The selection follows a...Read more
Nov 16, 2021
Nov 16, 2021

byprotokinetixp

Many biotech companies have seen soaring valuations as rapid advances in biotechnology have resulted in innovative new therapies. But how can wary investors find the right companies to back — companies like ProtoKinetix (PKTX), with lean corporate management, a world-class research team, and a robust pipeline of promising research? Although biotech investing can seem like...Read more
Marietta, Ohio, May 12, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”)    (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of AAGP® (PKX-001) in ocular conditions, specifically Dry Eye Disease and Wet and Dry forms of Age-related Macular Degeneration. The ProtoKinetix-IQVIA collaboration will aim to accelerate...Read more
May 04, 2021
Exciting things are happening at ProtoKinetix. Our clinical research is driving forward, we’re forming dynamic new partnerships, and we are poised to witness some incredible developments using our patented anti-aging glycopeptide, AAGP®. Learn more about what’s happening at ProtoKinetix, including AAGP® and our journey to market. Why we’re excited One of our goals in developing...Read more
Marietta, Ohio, April 22, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced Phase I clinical trials of AAGP® (PKX-001) treated islet cells have resumed at the University of Alberta, Edmonton. All clinical trials were paused in 2020 due to COVID-19 restrictions in the province. The Phase 1...Read more
Marietta, Ohio, April 14, 2021 ProtoKinetix, Incorporated (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP®. For the development of this drug for...Read more
Marietta, Ohio, April 7, 2021                                                                                                             ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the publication of a peer reviewed research paper describing and interpreting the results examining the benefit provided by AAGP® to enable human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to restor vision in an...Read more
Jan 22, 2021
Imagine the ability to fully recover from Type 1 diabetes and no longer live your life according to insulin. Imagine a future where we can overcome blindness. AAGP, the glycopeptide developed by ProtoKinetix, has the power to transform regenerative medicine, paving the path toward incredible medical results. “This product, and this company, has the ability...Read more
Marietta, Ohio, November 24, 2020                                                                                           ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing and interpreting the results analysing the benefit of PKX-001 on human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to an experimental model of blindness due to...Read more
Oct 30, 2020
The promise of biotechnology stocks to the average investor is the potential for blazing growth and incredible returns. But not every company pays dividends on that promise. Too many times, investors have been burned by biotech stocks that burn fast and bright before completely flaming out. What these investors are looking for is not just...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule